Skip to main content

Table 2 Health burden by housing type (Nā€‰=ā€‰16,381,935 weighted)

From: The health and wellbeing of Australian social housing tenants compared to people living in other types of housing

Ā 

Social housing (Nā€‰=ā€‰441,963, 2.7%)

% (SE)a

Private rental

(Nā€‰=ā€‰3,316,040, 20.2%)

% (SE)a

Home owner

(Nā€‰=ā€‰5,738,797, 35.0%)

% (SE)a

Home owner/ mortgagee

(Nā€‰=ā€‰6,885,135, 42.0%)

% (SE)a

Self-assessed health status

Ā Ā Ā Ā 

ā€ƒExcellent

7% (1.27)

21% (1.10)

18% (0.67)

23% (0.73)

ā€ƒVery Good

15% (1.96)

36% (1.17)

34% (0.78)

39% (0.81)

ā€ƒGood

33% (2.42)

31% (1.00)

30% (0.76)

28% (0.65)

ā€ƒFair

28% (2.31)

9% (0.74)

14% (0.59)

8% (0.42)

ā€ƒPoor

17% (1.74)

2.9% (0.36)

5% (0.38)

1.9% (0.22)

Psychological distress

Ā Ā Ā Ā 

ā€ƒLow distress level/Unable to determine

41% (2.66)

56% (1.26)

68% (0.75)

66% (0.84)

ā€ƒModerate distress level

26% (2.36)

26% (1.24)

20% (0.72)

23% (0.71)

ā€ƒHigh distress level

18% (2.21)

12% (0.83)

8% (0.55)

8% (0.44)

ā€ƒVery high distress level

16% (1.60)

5% (0.56)

3.4% (0.34)

3.1% (0.32)

Disability

Ā Ā Ā Ā 

ā€ƒProfound/severe core activity limitation

15% (1.80)

2.6% (0.36)

6% (0.32)

2.3% (0.25)

ā€ƒModerate/mild core activity limitation

44% (3.15)

15% (0.84)

28% (0.73)

13% (0.52)

ā€ƒNo activity limitation

41% (3.12)

82% (0.92)

67% (0.75)

84% (0.57)

Selected current long-term conditions

Ā Ā Ā Ā 

ā€ƒAsthma

22% (2.00)

10% (0.65)

11% (0.54)

12% (0.53)

ā€ƒCancer

4.3% (1.07)

0.6% (0.16)

4.6% (0.32)

1.3% (0.19)

ā€ƒKidney disease

2.8% (0.84)

0.7% (0.18)

2.2% (0.23)

0.5% (0.11)

ā€ƒArthritis

36% (2.82)

9% (0.56)

33% (0.72)

13% (0.63)

ā€ƒDiabetes mellitus

15% (1.70)

3.9% (0.47)

10% (0.56)

3.6% (0.31)

ā€ƒHeart or circulatory problems

13% (1.93)

3.3% (0.40)

11% (0.46)

3% (0.26)

ā€ƒMental and behavioural problems

43% (2.35)

25% (0.97)

21% (0.87)

19% (0.70)

ā€ƒOsteoporosis

9% (1.64)

1.6% (0.27)

10% (0.42)

2.6% (0.27)

ā€ƒMean number of selected conditions

Ā Ā Ā Ā 

ā€ƒā€ƒ0

29% (2.70)

61% (1.08)

41% (0.92)

61% (0.85)

ā€ƒā€ƒ1

31% (2.37)

27% (1.10)

31% (0.91)

27% (0.79)

ā€ƒā€ƒ2

18% (1.94)

9% (0.67)

17% (0.59)

8% (0.53)

ā€ƒā€ƒ3+

23% (2.57)

2.8% (0.39)

11% (0.48)

3.3% (0.30)

Other long-term conditions

Ā Ā Ā Ā 

ā€ƒAny (yes)

57% (2.81)

27% (1.00)

49% (0.80)

32% (0.74)

ā€ƒTop five other conditions

Ā Ā Ā Ā 

ā€ƒā€ƒBack problems

32% (2.34)

18% (0.91)

23% (0.78)

20% (0.70)

ā€ƒā€ƒHypertensive disease

25% (2.18)

6% (0.53)

24% (0.73)

9% (0.40)

ā€ƒā€ƒHigh cholesterol

13% (1.78)

3.5% (0.43)

14% (0.61)

5% (0.35)

ā€ƒā€ƒCOPDb (bronchitis/emphysema)

11% (1.35)

2.4% (0.37)

3.9% (0.36)

2% (0.23)

ā€ƒā€ƒTachycardia

5% (1.13)

1.2% (0.25)

4.4% (0.31)

1.2% (0.15)

Overweight / Obese

Ā Ā Ā Ā 

ā€ƒYes

72% (3.12)

63% (1.22)

70% (0.74)

67% (0.78)

Health risk behaviours

Ā Ā Ā Ā 

ā€ƒCurrent daily smoker

37% (2.38)

21% (0.93)

9% (0.48)

11% (0.53)

ā€ƒAlcohol lifetime

13% (1.96)

16% (0.84)

17% (0.71)

17% (0.62)

ā€ƒAlcohol short-term

30% (2.38)

50% (1.15)

31% (0.71)

50% (0.80)

ā€ƒInadequate fruit and/or veg

97% (0.76)

96% (0.37)

93% (0.43)

95% (0.36)

ā€ƒInadequate physical activity

91% (1.60)

85% (0.89)

83% (0.70)

85% (0.58)

ā€ƒNumber of health risk behaviours

Ā Ā Ā Ā 

ā€ƒā€ƒ0ā€“1

7% (1.35)

7% (0.54)

14% (0.59)

8% (0.54)

ā€ƒā€ƒ2

47% (3.21)

44% (1.29)

55% (0.84)

47% (0.79)

ā€ƒā€ƒ3+

45% (2.95)

49% (1.21)

30% (0.77)

45% (0.81)

Overall number health burden factors

Ā Ā Ā Ā 

ā€ƒ0

7% (2.42)

15% (0.98)

12% (0.60)

13% (0.53)

ā€ƒ1

15% (2.02)

32% (1.15)

26% (0.76)

32% (0.75)

ā€ƒ2

21% (2.15)

30% (1.13)

31% (0.92)

32% (0.90)

ā€ƒ3

17% (1.64)

14% (0.87)

17% (0.75)

15% (0.57)

ā€ƒ4

16% (2.09)

6% (0.54)

8% (0.50)

4.7% (0.35)

ā€ƒ5

12% (1.67)

2.5% (0.39)

4.1% (0.30)

2.2% (0.23)

ā€ƒ6ā€“7

12% (1.58)

1.4% (0.22)

2.1% (0.19)

0.8% (0.14)

Mean (SE) overall health burden score

3.1 (0.12)

1.8 (0.03)

2.0 (0.02)

1.8 (0.02)

  1. SEā€‰=ā€‰standard error
  2. aPopulation weighted
  3. bChronic obstructive pulmonary disease